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A B S T R A C T
BACKGROUND: We have recently identified a variant form of the human 2B-adreno-
receptor (AR) gene. Based on the coronary vasoconstrictive property of 2-adrenore-
ceptors in humans, we hypothesized that the naturally occurring D (deletion) variant 
confers reduced receptor desensitization and therefore increased vasoconstriction in 
humans. This property could be associated with cardiovascular pathologies such as 
acute myocardial infarction (AMI) and sudden cardiac death (SCD). To test this hy-
pothesis, we carried out two separate clinical genetic studies in middle-aged Finnish 
men, reported in two separate original publications.
METHODS: We examined a subset (912 men, aged 46 to 64 years) of the Kuopio Isch-
emic Heart Disease Risk Factor Study, an ongoing prospective population-based 
study investigating risk factors for cardiovascular diseases and related outcomes in 
men from eastern Finland (Prospective Follow-up study). Seven hundred out-of-hospi-
tal deaths of Finnish men in the Helsinki region were subjected to autopsy and formed 
the basis of the second, cross-sectional study investigating the associations between 
the 2B-AR I/D polymorphism and coronary heart disease (Autopsy study). DNA for 
genotyping was extracted using standard methods. The 2B-adrenoreceptor insertion/
deletion (I/D) genotypes were determined using PCR-amplification and DNA elec-
trophoresis.
RESULTS: Of the 912 subjects, 192 (21%) had the D/D genotype, 256 (28%) had the 
I/I genotype, and 464 (51%) were heterozygous. Thirty-seven acute coronary events 
occurred during the follow-up time: 15 in the D/D genotype group (7.8%), 12 in the 
I/D group (2.6%), and 10 in the I/I group (3.9%). Using a univariate analysis, the risk 
for an acute coronary event differed significantly between the three genotype groups 
(p=0.017). The D/D genotype group had a 3-fold increased risk for an acute coronary 
event in comparison with the I/D group (95% CI=1.4–6.5, p=0.004), and a non-sig-
nificantly increased risk of 1.9 relative to the I/I genotype group (95% CI=0.8–4.1, 
p=0.128). In a Cox proportional hazards’ model adjusting for several variables, the 
relative risk associated with the D/D genotype was 2.2 (95% CI=1.1–4.4, p=0.02). 
In the autopsy cohort, 2B-AR I/D genotyping was accomplished for 683 men (98%). 
Of these, 152 (22%) had the D/D genotype, 186 (27%) had the I/I genotype, and 345 
(51%) were heterozygous. The D/D genotype was associated with an increased risk for
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i N T R O D U C T i O N
Three human 2-adrenoceptor (2-AR) subtypes have 
been identified and named 2A-AR, 2B-AR, and 2C-AR. 
Current drugs are not sufficiently 2-AR subtype-selective, 
which complicates the investigation of the physiologic roles and 
therapeutic potential of the 2-AR subtypes. New insight into 
the roles of the different 2-AR subtypes in regulation of the 
cardiovascular system was recently achieved with strains of ge-
netically engineered (knock-out, KO) mice deficient in either 
2A-AR or 2B-AR or 2C-AR.1-3 The results of these studies 
suggest that the 2C-AR subtype does not affect either blood 
pressure or vasoconstriction, that the 2A-AR mediates the 
central hypotensive effects of clonidine-like 2-AR agonists, 
and that the 2B-AR mediates peripheral vasoconstriction.4 
The tissue distributions of the 2-AR subtypes are not known 
in detail in humans, and the extent of 2B-AR expression in 
vascular tissues is unknown. Some studies have failed to detect 
2B-AR expression in the aorta of experimental animals,5,6 
but others have reported that 2B-ARs are expressed in rat 
vascular smooth muscle cells,7 in human8 and rat kidney,9 
and in central pathways of the autonomic nervous system.10 A 
recent in vivo study in humans demonstrated that activation 
of 2-ARs reduces coronary blood flow, in both normal and 
atherosclerotic arteries.11
We have recently identified a variant form of the human 
2B-AR gene.12 The variant allele encodes a receptor protein 
with a deletion of 3 glutamate residues in an acidic stretch of 
18 amino acids located in the third intracellular loop of the 
receptor. This acidic stretch is a unique feature in the primary 
structure of 2B-AR in comparison to 2A-AR and 2C-AR. 
Sequence alignment of 2B-AR polypeptides from different 
mammals reveals that the acidic stretch is conserved in mam-
malian 2B-ARs, and that the acidic stretch is long in humans 
in comparison to other species. This suggests that the motif is 
important for the functionality of the receptor, and that the 
short form (“deletion”, D) perhaps represents the ancestral 
form and the long form (“insertion”, I) may represent a more 
recent allelic variant.
Negatively charged amino acids in the third intracellular 
loop of the 2A-AR are important for receptor phosphorylation 
by β-adrenoceptor kinase,13 and a similar role was considered 
possible for the negatively charged motif in 2B-AR. Jewell-
Motz and Liggett14 used site-directed mutagenesis to delete 
and to substitute 16 amino acids of the stretch in vitro. The 
wild-type 2B-AR underwent ~52% functional desensitization 
in transfected cells while agonist-promoted desensitization 
was ablated in both mutated receptors. The mutated receptors 
underwent agonist-promoted phosphorylation at levels of only 
45-50% relative to the wild-type 2B-AR. The same group also 
showed that the naturally occurring polymorphic D variant 
similarly impairs agonist-promoted receptor desensitization.15 
Thus, the natural polymorphism determines the susceptibility 
of the receptor to modulation by a key mechanism of dynamic 
regulation.
Based on the coronary vasoconstrictive property of 2-ARs 
in humans, the peripheral vasoconstrictive property of the 2B-
AR subtype in mice, and the significance of this acidic region 
for the desensitization of the receptor, we hypothesized that 
the naturally occurring D variant confers reduced receptor 
desensitization and therefore increased vasoconstriction in 
humans. This property could be associated with cardiovas-
cular pathologies such as myocardial infarction and sudden 
cardiac death. To test this hypothesis, we carried out two 
separate clinical genetic studies in middle-aged Finnish men, 
reported in two separate original publications16 (Snapir et al, 
unpublished). Both studies had appropriate Ethics Commit-
tee approval.
M A T E R i A L S  A N D  M E T H O D S
P R O S P E C T i v E  f O L L O W - U P  S T U D y
We examined a subset of the Kuopio Ischemic Heart 
Disease Risk Factor Study, an ongoing prospective popula-
tion-based study investigating risk factors for cardiovascular 
diseases and related outcomes in men from eastern Finland.17 
This region is known for its homogenous population18 and 
high coronary morbidity and mortality rates.19 Our study was 
based on a representative population sample of 912 men, aged 
46 to 64 years at the start of follow-up. All subjects gave their 
written informed consent. The average time of follow-up was 
4.5 years (range 1 to 7.6 years).
To assess the occurrence of acute coronary events, diag-
nostic information was collected from the Finnish hospital 
discharge registry, which covers all inpatient admissions into 
all hospitals and district health centers in Finland. These data 
were classified by an internist using WHO MONICA criteria. 
An acute coronary event was defined either as a definite acute 
myocardial infarction (AMI) or a possible AMI, based on 
SCD and prehospital fatal AMI, with adjusted odds ratios (OR) of 1.8 - 2.4 compared to the other two genotypes (p <0.05).
CONCLUSiON: the D variant of the 2B-AR gene is a causal risk factor for AMI and SCD in Finnish men. Further genetic epide-
miological studies are still needed to confirm the causality and to test its generalization to other populations, and its physiologi-
cal in vivo effects need to be identified.
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ECG, clinical, laboratory or autopsy findings, or as an episode 
of acute chest pain of >20 min without diagnostic ECG or 
enzyme findings, but requiring hospitalization (prolonged 
chest pain). Only first events were analyzed; a subject was 
excluded from further analysis when an acute coronary event 
had occurred.
A U T O P S y  S T U D y
Seven hundred out-of-hospital deaths of Finnish men in the 
Helsinki region were subjected to medico-legal autopsy and 
formed the basis of the second, cross-sectional study investi-
gating the associations between the 2B-AR I/D polymorphism 
and CHD. The material included all prehospital first-attack 
AMI deaths in the source population.20 The methods used in 
diagnosis of AMI, measurement of coronary narrowing and 
coronary atherosclerosis, and assessment of risk factors for 
CHD and SCD have been described.20
D N A  E x T R A C T i O N  A N D  A N A Ly S i S
DNA for genotyping was extracted using standard meth-
ods. The 2B-AR insertion/deletion (I/D) genotypes were de-
termined using PCR-amplification and DNA electrophoresis. 
Identification of the I and D alleles was based on their 9 bp size 
difference. A few samples of each genotype were sequenced to 
confirm the PCR results. The region of interest was amplified 
using a sense primer 5’-AGG-GTG-TTT-GTG-GGG-CAT-
CT-3’ and an anti-sense primer 5’-CAA-GCT-GAG-GCC-
GGA-GAC-ACT-3’, yielding products sized 112 bp (I) and 
103 bp (D). To prevent observer bias, the investigators who 
collected the clinical data were blind to the subjects’ genotypes 
and the investigator who performed the genotyping was blind 
to all subject information. The genotyping result of each 
subject was insertion/insertion (I/I, which is a homozygous 
form of the published 2B-AR sequence,21 deletion/deletion 
(D/D, which is a homozygous form of the recently discovered 
variant) or insertion/deletion (I/D).
S T A T i S T i C A L  A N A Ly S i S
To assess the possible association of the 2-AR I/D poly-
morphism with the risk for an acute coronary event in the 
follow-up study population, univariate Cox regression analysis 
was performed. Next, multivariate Cox regression analysis 
was performed to assess the impact of possible confounding 
and modifying factors on the observed association. variables 
that were associated (p <0.10 in the above analyses) with the 
2B-AR I/D genotype were entered into a multivariate Cox 
regression model. The same procedure was performed for 
all variables that were previously identified as risk factors for 
CHD in this study population. The variables identified in these 
two models were entered together with all established major 
risk factors for CHD22 into a new multivariate Cox regression 
model. Logistic regression was used to analyze interactions 
between the α2B-AR I/D variation and known risk factors for 
CHD. In the autopsy study, analyses of the effect of geno-
type on the odds of AMI with and without thrombosis, and 
comparisons between acute thrombosis cases and other SCD 
victims were based on logistic regression with and without the 
risk factor data. The interactions between genotype, age, and 
cause of death were also analyzed using logistic regression 
with Scheffe’s post-hoc test.
R E S U L T S
P R O S P E C T i v E  f O L L O W - U P  S T U D y
Of the 912 subjects, 192 (21%) had the D/D genotype, 256 
(28%) had the I/I genotype, and 464 (51%) were heterozygous. 
Thirty-seven acute coronary events occurred during the fol-
low-up time: 15 in the D/D genotype group (7.8%), 12 in the 
I/D group (2.6%), and 10 in the I/I group (3.9%). Of these 37 
acute coronary events, 18 were classified as definite AMI, 12 
as possible AMI and 7 as prolonged chest pain. Using a uni-
variate Cox regression model, the risk for an acute coronary 
event differed significantly between the three genotype groups 
(p=0.017). The D/D genotype group had a 3.0 times increased 
risk for an acute coronary event in comparison with the I/D 
group (95% CI=1.4–6.5, p=0.004), and a non-significantly 
increased risk of 1.9 relative to the I/I genotype group (95% 
CI=0.8–4.1, p=0.128). The relative risk of the I/D genotype 
group was not significantly different from that of the I/I group 
(RR=0.6, 95% CI=0.3–1.4, p=0.251). We also applied the 
same analysis only to events classified as definite or possible 
AMI, excluding the prolonged chest pain category of the 
FINMONICA coronary event classification (30 events). In 
this analysis (overall p=0.002), the relative risk of the D/D 
group was significantly different from the I/D (RR=4.1, 95% 
CI=1.8–9.3, p=0.0009) and the I/I groups (RR=3.1, 95% 
CI=1.2–8.0, p=0.02). The risk ratio between the I/D and I/I 
groups was not significantly different from unity (RR=0.8, 
95% CI=0.3–2.1, p=0.6). These results suggest that the D 
allele confers its effect on the risk for coronary events in a 
recessive mode of inheritance.
In a univariate Cox regression model, the D/D genotype 
was associated with an acute coronary event risk of 2.5 (95% 
CI=1.3–4.8, p=0.006) relative to the combined I/D + I/I 
group. A Kaplan-Meier survival function of event-free time 
(Fig. 1) illustrates the consistent difference in incidence of 
acute coronary events in the D/D group compared to the I/D 
+ I/I group. A Cox regression analysis limited to the definite 
or possible AMI cases, excluding the prolonged chest pain 
category, revealed a relative risk of 3.7 (95% CI=1.8–7.5, 
p=0.0006) for the D/D vs. the I/D + I/I group.
Eighty-seven variables were tested for their association 
with the 2B-AR I/D polymorphism to explore possible con-
founding factors. The genotype groups were not different in 
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terms of known major risk factors for CHD. 22) Only three 
variables were significantly different (p <0.05) between the 
genotype groups. The D/D group had more acute coronary 
events. This group also had a slightly higher mean level of 
blood hemoglobin, and more common ischemic findings in 
exercise ECG and a lower mean four-day dietary cholesterol 
intake.16 In addition, the 2B-AR I/D polymorphism was non-
significantly (0.1> p >0.05) associated with BMI (I/I> D/D 
>I/D). Thus, the blood hemoglobin concentration, ischemic 
findings in exercise ECG, the mean four-day dietary choles-
terol intake, and BMI were introduced into a Cox regres-
sion model together with the variables that were previously 
described as AMI risk factors in this study population. Out 
of these variables, hypertension, LDL cholesterol level, and 
family history of CHD were identified by this model as inde-
pendent AMI risk factors.
In a Cox proportional hazards’ model adjusting for age, se-
rum LDL and HDL cholesterol levels, smoking, hypertension, 
BMI, diabetes, and family history of CHD, the relative risk 
associated with the D/D genotype was 2.2 (95% CI=1.1–4.4, 
p=0.02). The relative risk was 3.2 (95% CI=1.5–6.7, p=0.002) 
when the analysis was performed using only the definite and 
the probable AMI events (n=30). When only men with no 
history of CHD were included in the analysis, the adjusted 
relative risk associated with the D/D genotype was 2.2 (95% 
CI=1.0–5.0, p=0.06)16.
A U T O P S y  S T U D y
2B-AR I/D genotyping was accomplished for 683 men 
(98%). Of these, 152 (22%) had the D/D genotype, 186 (27%) 
had the I/I genotype, and 345 (51%) were heterozygous. No 
differences (p >0.1) were found in major risk factors for 
CHD between the 2B-AR I/D genotype groups. Multivariate 
analyses revealed that coronary narrowing percentages and 
areas of atherosclerotic lesions were similar in the D/D and 
in the I/I + I/D genotype groups suggesting that variation 
in this genetic locus was not involved in the development of 
coronary atherosclerosis. The D/D genotype was associated 
with an increased risk for SCD and prehospital fatal AMI, with 
adjusted odds ratios (OR) of 1.8 - 2.4 compared to the other 
two genotypes (p <0.05). The I/D and the I/I genotypes were 
not different in respect to odds of SCD and AMI. When the 
data were analyzed assuming a recessive inheritance model, 
comparing the D/D genotype with the combined I/D + I/I 
genotypes, the D/D genotype again conferred an increased 
risk for SCD and AMI, especially for AMI without macro-
scopic thrombus (Table 1). The risks associated with the D/D 
genotype were considerably higher in a subpopulation of men 
who died suddenly before the age of 55.
D i S C U S S i O N
Our prospective follow-up cohort study was the first to 
indicate that there is a strong statistical association between 
the D/D genotype of the 2B-AR and an increased risk for 
acute coronary events. Men with the D/D genotype had 2.5 
times the risk to experience an acute coronary event relative 
to men with the I/D and the I/I genotypes, independently of 
other major risk factors for CHD.
Our autopsy-based study confirmed that the D/D genotype 
of the 2B-AR I/D variation is associated with an increased 
risk for AMI and SCD in Finnish men, especially in men who 
died before the age of 55. This association was largely due to 
the increased risk of the D/D genotype of non-thrombotic fatal 
prehospital AMI. Analysis of the coronary arteries revealed 
similar narrowing and other indices of atherosclerosis in the 
2B-AR I/D genotype groups. The study thus suggested that 
the 2B-AR I/D polymorphism does not confer its increased 
risk for SCD and AMI through mechanisms directly related 
to progression of coronary atherosclerosis.
Our hypothesis that the D variant of the 2B-AR gene 
confers increased vasoconstriction is based on two premises: 
the impaired desensitization associated with the D variant, 
and the role of the 2B-AR subtype in vasoconstriction. The 
functional significance of this I/D polymorphism of the 2B-
AR gene was investigated in an in vitro cell culture model, and 
the results indicated that the D variant conferred impaired 
receptor desensitization under prolonged agonist activation.15) 
The assumption that the 2B-AR is critically involved in the 
regulation of vasoconstriction cannot be directly tested in 
vivo in humans, as subtype-selective 2B-AR drugs are not 
(yet) available. Studies in KO mice have clearly documented 
a prominent role for the 2B-AR in vasoconstriction. 1) Even 
fiGURE 1.
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if the perception of the 2B-AR subtype as an important 
mediator of vasoconstriction is based on studies in KO mice, 
the similar blood pressure responses to 2-AR agonists in 
humans and laboratory rodents1 suggest that the 2B-AR is a 
major mediator of vasoconstriction also in humans.
Augmentation in the constrictive properties of coronary 
arteries may be involved in the increased incidence of acute 
coronary events indirectly as the cause for intimal tearing 
leading to AMI or directly as in coronary artery spasm.23,24  
Increased vasoconstriction may lead to increased ischemic 
findings and coronary events in the D/D group by at least two 
additional mechanisms: 1. decreased coronary blood flow due 
to increased vasoconstriction of small coronary arteries and 
by 2. increased total peripheral resistance, causing increased 
cardiac work load and oxygen demand.
Our analysis did not disclose a mechanism by which the 
D/D genotype confers an increased risk for SCD and AMI. 
However, taking into account the role of 2B-AR in vaso-
constriction,4 and that rupture of atherosclerotic lesions can 
induce rapid and marked increases in distal vascular resistance 
due to severe microvascular vasoconstriction,25 our results 
may suggest that carriers of the D/D genotype are particularly 
prone to vasoconstriction in the vicinity of preexisting stenotic 
lesions in the epicardial coronary arteries or spasm of small-
caliber coronary branches nourishing the subendocardium. 
These mechanisms may then contribute to the fatality of the 
ongoing coronary event.
C O N C L U S i O N S
The physiological functions of the 2B-AR subtype in mice, 
the impaired desensitization properties of the human D vari-
ant in vitro, and our unbiased clinical genetic study designs 
and consistent results allow us to suggest that the D variant of 
the 2B-AR gene is a causal risk factor for AMI and SCD in 
Finnish men. Further genetic epidemiological studies are still 
needed to confirm the causality and to test its generalization to 
other populations, and its physiological in vivo effects need to 
be identified. The lack of a proven in vivo mechanism weakens 
the strength of the associations and necessitates further stud-
ies on the physiological effects of this genetic variant on the 
human cardiovascular system.
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